Consider this: of the trillions upon trillions of cells in the human body, only about 1 in 10 is actually human. The rest belong to microbes, which colonize every inch of you, from the inside of your mouth to the skin between your toes. It’s no wonder, then, that research is increasingly finding that the diversity of these microbes has important effects on health.
The vast majority of microbes — perhaps up to 100 trillion of them — live in our guts. So-called gut bugs help digest our food, assist our immune systems, maintain the health of the intestines, produce vitamins, aid metabolism and extract calories from food (which is why much research has associated gut bugs with obesity).
To better understand the way gut bugs work, a new study has aimed to categorize the lot of them. The study, led by Peer Bork of the European Molecular Biology Laboratory in Heidelberg, Germany, found that the bacteria in our guts falls into one of three distinct ecosystems, or "enterotypes."
"The three gut types can explain why the uptake of medicines and nutrients varies from person to person," Jeroen Raes, a bioinformatician at Vrije University in Brussels and coauthor of the new study, said in a statement. Which means that knowing a person’s enterotype could someday help doctors tailor drug treatments or diets to suit them better.
Or, [Bork] speculated, doctors might be able to use enterotypes to find alternatives to antibiotics, which are becoming increasingly ineffective. Instead of trying to wipe out disease-causing bacteria that have disrupted the ecological balance of the gut, they could try to provide reinforcements for the good bacteria. "You’d try to restore the type you had before," he said.
For the new study, the research team evaluated stool samples from 22 European individuals, extracted the DNA and determined its composition by using DNA analysis and computers. They also compared the results to other published findings from Japanese and American subjects.
Scientists found that each of the three enterotypes was composed of a unique balance of microbe species. The team named each type after its dominant bacteria: Bacteroides, an enterotype that’s known to break down carbohydrates and is better at making vitamins B2, B5, C and H; Prevotella, which degrades mucus and produces more B1 and folic acid; and Ruminococcus, which…
A team of scientists published a paper today in the journal Science which provides some hopeful news.
Specifically, a team of scientists have discovered a new species of oil-eating microbes which thrive in the deepwater of the Gulf of Mexico:
The biological effects and expected fate of the vast amountof oil in the Gulf of Mexico from the Deepwater Horizon blowoutare unknown due to the depth and magnitude of this event. Here,we report that the dispersed hydrocarbon plume stimulated deep-seaindigenous -proteobacteria that are closely related to knownpetroleum-degraders. Hydrocarbon-degrading genes coincided withthe concentration of various oil contaminants. Changes in hydrocarboncomposition with distance from the source and incubation experimentswith environmental isolates demonstrate faster-than-expectedhydrocarbon biodegradation rates at 5°C.
Even better, the scientists believe that this new species (pronounced "gamma-proteo-bacteria") may not suck up as much oxygen as previously-discovered species:
Based on theseresults, the potential exists for intrinsic bioremediation ofthe oil plume in the deep-water column without substantial oxygendrawdown.
A newly discovered type of oil-eating microbe is suddenly flourishing in the Gulf of Mexico.
Their findings are based on more than 200 samples collected from 17 deepwater sites between May 25 and June 2. They found that the dominant microbe in the oil plume is a new species, closely related to members of Oceanospirillales.
[Lead author Dr. Terry Hazen, co-director of the Earth Sciences Division of the Lawrence Berkeley National Laboratories], suggested that the bacteria may have adapted over time due to periodic leaks and natural seeps of oil in the Gulf.
Scientists also had been concerned that oil-eating activity by microbes would consume large amounts of oxygen in the water, creating a "dead zone" dangerous to other life. But the new study found that oxygen saturation outside the oil plume was 67-percent while within the plume it was 59-percent.
It’s the ultimate science experiment, really — taking a handful of chemicals, mixing them in just the right combination and presto — life!
And after nearly 15 years of such toiling in his labs in Rockville, Md., J. Craig Venter, co-mapper of the human genome, has done just that. Reporting in the journal Science, he describes a remarkable experiment in which he and the team at his eponymous institute have pieced together the entire genome of a bacterium and then inserted those genetic instructions into another bacterium. The cell booted up, and life — by nearly any definition — was created.
"We’re basically getting new life out of the computer," Venter says. "We started with a genetic code in the computer, wrote the ‘software,’ put it into the cell and transformed it biologically into a new species. We’re still stunned by it as a concept."
With Venter’s breakthrough it’s now possible to splice and snap together genetic material to create a Legoland’s worth of new genetic combinations. Ideally, some of these would have robust industrial purposes, such as manufacturing bacteria that can churn out valuable vaccine components to shorten production times during an epidemic, or co-opting organisms such as algae to pump out new sources of biofuel-based energy.
"Just imagine these cells where all we do is put in a new piece of chemical software and all the characteristics of the cell start changing to become what was dictated by the new software," says Venter. "These are biological transformers."
The paper is the final and most critical step toward realizing what began as scientific curiosity among the scientists at the J. Craig Venter Institute back in the early 1990s, when many of the same researchers first succeeded in sequencing the entire genome of a self-replicating organism, the bacterium Haemophilus influenzae. That led to the generation of the complete sequencing of the smallest known genome, at 582,000 base pairs, belonging to another bacterium, Mycoplasma genitalium. Such smallness was intriguing because it led Venter to the philosophical question that inspired the current research — what was the minimum genome required to create life in the lab?
For the study just released, the answer turned out to be about 1 million, and the paper describes how he did it. DNA is made up of millions of…
Here’s some weekend reading in advance. Consider throwing away economic models based on the misconception that people behave rationally and start anew with the premise that we are like mindless bacteria. – Ilene
Old-time economics saw investors as rational individuals, all behaving autonomously in a logical fashion, rather like Mr. Spock umbilically attached to Deep Thought. Today not even economists really believe that this is how people actually operate, but figuring out something better is a not insignificant task. Psychologists, however, have long known that what happens in the gaps between people is as important as what happens in the gaps between their ears – so is there something going on in the interactions between investors, which causes market instability?
One possible answer comes from the study of bacteria. Just as we might have suspected all along, stockmarket investor behaviour can be modelled by examining the way a bunch of brainless, single celled and barely animate creatures interested only in food and reproduction disport themselves on a Petri plate. Sometimes analogies are just too sweet.
The critical thing about any economic model is that it arrives at results that look like what we actually see in markets. Mostly the jargon fixated commentators who dominate the media are happy to talk in terms of business cycles when, in reality, the only cycles seen in most investing circles are the ones used by the boys and girls delivering lunchboxes. What we actually get, if we look at stockmarkets and stock prices, is something that looks like the readout we see from a seismograph when an earthquake occurs.
If we start by making a few assumptions about what investors actually do in real life – like, for instance, that they don’t behave rationally and that they tend to copy successful behaviour from people they’re closely connected to – we can rapidly create a model that produces outputs that look very different from those generated by models of people who behave independently and rationally. In fact the output of these models looks a lot like the readout we see from a seismograph when an earthquake occurs.
So it seems that the interactions between investors and how these interactions affect their willingness or otherwise to invest is the critical thing in these models.…
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at firstname.lastname@example.org with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
Today's release of the August Producer Price Index (PPI) for Final Demand was unchanged month-over-month seasonally adjusted. Core Final Demand was up 0.1% from last month. Investing.com correctly forecast Core PPI but was looking for a comparable 0.1% increase in the headline number.
The unadjusted year-over-year change in Final Demand is up 1.8%, up slightly from last month's YoY of 1.7%.
Here is the essence of the news release on Finished Goods:
The Producer Price Index for final demand was unchanged in August, seasonally adjusted, the U.S. Bureau of Labor Statistics reported today. Final demand prices advanced 0.1 percent in July and 0.4 percent in June. On an unadjusted basis, the index for final demand increased 1.8 percent for the 12 months ended in August......
As the Scotish independence vote draws near and remains too close to call, some analysts are suggesting Plan B for Scotland may be to choose to opportunistically default. This has done nothing to calm concerns of the aftermath of a "yes" vote - despite US asset managers proclaiming it irrelevant. Nowhere is that more clear than, as The Independent reports, Britain’s banks have been quietly moving millions of banknotes north of the border to cope with any surge in demand by Scots to withdraw cash in the even...
If GOOGLE, the NSA, and Bill Gates all got together in a room with the task of building the most accurate trading algorithm… it wouldn’t just be any ordinary system… it’d be the greatest trading algorithm in the world.
Well, I hate to break it to you… they never got around to building it, but my colleagues at Market Tamer did.
Although the stock market displayed weakness last week as I suggested it would, bulls aren’t going down easily. In fact, they’re going down swinging, absorbing most of the blows delivered by hesitant bears. Despite holding up admirably when weakness was both expected and warranted, and although I still see higher highs ahead, I am still not convinced that we have seen the ultimate lows for this pullback. A number of signs point to more weakness ahead.
In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, review our weekly fundamentals-based SectorCast rankings of the ten U.S. business sectors, and then offer up some actionable trading ideas, including a sector rotation strategy using ETFs and an enhanced version using top-r...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
In a report published Monday, Compass Point analyst Michael Tarkan reiterated a Buy rating and $21.00 price target on Navient Corp (NASDAQ: NAVI).
In the report, Compass Point noted, “We reiterate our Buy rating on NAVI shares after analyzing updated credit data within the company's private student loan trusts, which indicate continued YOY improvement in delinquency and default rates. The data captures statistics for trusts originated from 2002 through 2014 for the three months ended August 31, 2014, providing a good leading indicator for 3Q14 credit trends. The ongoing improvement should give management flexibility to continue to lower provision expenses to drive earnings higher.”
The CBOE Vix Index is in positive territory on Friday morning as shares in the S&P 500 Index move slightly lower. Currently the VIX is up roughly 2.75% on the session at 13.16 as of 11:35 am ET. Earlier in the session big prints in October expiry call options caught our attention as one large options market participants appears to have purchased roughly 106,000 of the Oct 22.0 strike calls for a premium of around $0.45 each. The VIX has not topped 22.0 since the end of 2012, but it would not take such a dramatic move in the spot index in order to lift premium on the contracts. The far out-of-the-money calls would likely increase in value in the event that S&P500 Index stocks slip in the near term. The VIX traded up to a 52-week high of 21.48 back in February. Next week’s release of the FOMC meeting minutes f...
Despite the various opinions on Bitcoin, there is no question as to its ultimate value: its ability to bypass government restrictions, including economic embargoes and capital controls, to transmit quasi-anonymous money to anyone anywhere.
Opinions differ as to what constitutes "money."
The English word "money" derives from the Latin word "moneta," which means to "mint." Historically, "money" was minted in the form of precious metals, most notably gold and silver. Minted metal was considered "money" because it possessed luster, was scarce, and had perceive...
Author Helen Davis Chaitman is a nationally recognized litigator with a diverse trial practice in the areas of lender liability, bankruptcy, bank fraud, RICO, professional malpractice, trusts and estates, and white collar defense. In 1995, Ms. Chaitman was named one of the nation's top ten litigators by the National Law Journal for a jury verdict she obtained in an accountants' malpractice case. Ms. Chaitman is the author of The Law of Lender Liability (Warren, Gorham & Lamont 1990)... Since early 2009, Ms. Chaitman has been an outspoken advocate for investors in Bernard L. Madoff Investment Securities LLC (more here).
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Well PSW Subscribers....I am still here, barely. From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.
First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices. Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment. Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer. For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither MaddJack Enterprises, LLC
d/b/a PhilStockWorld (PSW) nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.